Clinical Trials

rEECur

International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

Euro Ewing 2012 (closed)

International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours

iEuroEwing

Chief Investigator: Uta Dirksen, University Hospital Essen, Germany

INTER-EWING-1

Chief Investigator: Bernadette Brennan, University of Manchester

Euro Ewing 2012

1. Brennan B, Kirton L, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Fenwick N, Strauss S, Moroz V, Whelan J, Wheatley K. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. Lancet. 2022 Oct 29;400(10362): 1513-1521.
2. ASCO (2020) Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012) [Abstract]
3. Trials (2020) International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours [Protocol paper]

rEECur

1. ASCO (2022) Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES) [Abstract]
2. ASCO (2020) Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial. [Abstract]
3. ASCO (2020) Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES) [Abstract]
4. ASCO (2019) Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma [Abstract]